Somers EC, Eschenauer GA, Troost JP, et al
Somers EC, Eschenauer GA, Troost JP, et al.. death, intensive care unit (ICU) admission risk, air flow requirement, and secondary infection. Results: A total of 12 qualified literature including 8979 COVID-19 individuals were recruited, and they were divided into experimental group ( em n /em ?=?2673) and control group ( em n /em ?=?6306). Using a random-effect model, it is found that the GM-CSF antibody treatment was associated with a 23% decrease of the risk of death [odds percentage (OR): 0.34, 95% confidence interval (CI): 0.21C0.56, em p /em ? ?0.0001] and a 20% enhancement of air flow (OR: 1.47, 95% CI: 1.19, 1.80, em p /em ?=?0.0002). GM-CSF antibody treatment did not have a significant correlation to secondary infection and improved risk of ICU admission in COVID-19 individuals, which…